Clinical Trial Update: The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

View source ↗

Summary

This clinical trial update discusses the efficacy and safety of adjuvant immunotherapy after pathological complete response following neoadjuvant chemoimmunothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Resectable/Potentially Resectable NSCLC | Status: ACTIVE_NOT_RECRUITING